C0220825||Assessment
C0543478||Residual Disease
C2985547||Molecular Breast Imaging
C0600558||Neoadjuvant Therapy
C0449560||Subtypes
C0220825||Assessment
C0543478||residual disease
C0600558||neoadjuvant therapy
C0006142||breast cancer
C0006141||breast
C0011923||imaging
C2603343||study
C0220825||evaluates
C2985547||molecular breast imaging
C2985547||molecular breast imaging
C1258740||cadmium zinc telluride
C0543478||residual disease
C0600558||neoadjuvant therapy
C0006142||breast cancer
C1516606||Clinical data
C0011923||imaging
C0243095||findings
C0043210||women
C0006142||breast cancer
C0600558||neoadjuvant therapy
C2985547||molecular breast imaging
C0243095||findings
C1710255||surgical pathology results
C2985547||molecular breast imaging
C4050242||complete pathological response
C0456389||size
C0543478||residual disease
C0449560||subtypes
C0456389||size
C2985547||molecular breast imaging
C3539878||triple negative
C2348909||HER2/neu positive
C0449560||subtypes
C4050242||complete pathological response
C2985547||molecular breast imaging
C0543478||residual disease
C3539878||triple negative
C2348909||HER2/neu positive
C2985547||molecular breast imaging
C0543478||residual disease
C0600558||neoadjuvant treatment
C0449560||subtype
C3539878||triple negative
C2348909||HER2/neu positive
C0449560||subtypes